Seroatlas · Human Serome Atlas

NMU

Neuromedin-U

Also known as: NMU_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P48645
Gene: NMU
Ensembl: ENSG00000109255
Chromosome: 4
Canonical length: 174 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted in other tissues

OverviewNCBI Gene

This gene encodes a member of the neuromedin family of neuropeptides. The encoded protein is a precursor that is proteolytically processed to generate a biologically active neuropeptide that plays a role in pain, stress, immune-mediated inflammatory diseases and feeding regulation. Increased expression of this gene was observed in renal, pancreatic and lung cancers. Alternative splicing results in multiple transcript variants encoding different isoforms. Some of these isoforms may undergo similar processing to generate the mature peptide. [provided by RefSeq, Jul 2015]

Canonical amino-acid sequenceUniProt

174 residues, UniProt reviewed canonical sequence.

>P48645|NMU
     1  MLRTESCRPR SPAGQVAAAS PLLLLLLLLA WCAGACRGAP ILPQGLQPEQ QLQLWNEIDD
    61  TCSSFLSIDS QPQASNALEE LCFMIMGMLP KPQEQDEKDN TKRFLFHYSK TQKLGKSNVV
   121  SSVVHPLLQL VPHLHERRMK RFRVDEEFQS PFASQSRGYF LFRPRNGRRS AGFI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NMU can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.6
Highest tissue expression: 96 nTPM

Expression across tissuesHPA

Tissue

esophagus: 96 nTPM
skin: 36 nTPM
vagina: 29 nTPM
cervix: 23 nTPM
salivary gland: 13 nTPM
bone marrow: 9.2 nTPM

Single-cell type

esophageal suprabasal cells: 581 nCPM
esophageal apical cells: 411 nCPM
esophageal basal cells: 344 nCPM
suprabasal keratinocytes: 234 nCPM
basal keratinocytes: 89 nCPM
erythrocyte progenitors: 49 nCPM

Immune cell

MAIT T-cell: 3.6 nTPM
memory CD4 T-cell: 1.1 nTPM
memory CD8 T-cell: 0.2 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM

Brain region

thalamus: 15 nTPM
spinal cord: 7.3 nTPM
hypothalamus: 5.5 nTPM
midbrain: 5.1 nTPM
medulla oblongata: 2.5 nTPM
pons: 1.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.9
gnomAD pLI: 0
gnomAD missense Z: 0.07
DepMap mean gene effect: -0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

signaling receptor binding
neuromedin U receptor binding
type 1 neuromedin U receptor binding
type 2 neuromedin U receptor binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

Neuromedin U, amidation site
Neuromedin U, C-terminal
Neuromedin-U
Neuromedin U

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NMU as an antibody target. Whether an autoantibody or antibody against NMU could matter depends on whether native NMU is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NMU is annotated as secreted, so native NMU circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label NMU as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...